Trial Profile

A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 01 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABM 1310 (Primary) ; Cobimetinib (Primary)
Indications CNS cancer; Glioblastoma; Glioma; Malignant melanoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors ABM Therapeutics

04 Jun 2024 Interim Results (Results: As of 28 Nov 2023, n=51 ) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
17 May 2024 Status changed from active, no longer recruiting to discontinued.
30 Jan 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com